No Data
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): When Will It Breakeven?
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
Goldman Sachs Downgrades Apellis Pharmaceuticals to Neutral From Buy, $36 Price Target
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Apellis Pharmaceuticals Price Target Announced at $36.00/Share by Goldman Sachs
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
been hot today but that's getting into buying range for me..... EBS middle size company that got a new CEO last year completely changed things around since for EBS. take a look at who owns EBS and how much together. this small float is trading around 50% since half or more is already bought up by insiders or tutes
